- Home
- MDAI vs NRSN Comparison
MDAI vs NRSN Comparison
Compare MDAI & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- NRSN
- Stock Information
- Founded
- MDAI 2013
- NRSN 2017
- Country
- MDAI United States
- NRSN Israel
- Employees
- MDAI N/A
- NRSN N/A
- Industry
- MDAI Medical/Dental Instruments
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- NRSN Health Care
- Exchange
- MDAI Nasdaq
- NRSN Nasdaq
- Market Cap
- MDAI 51.5M
- NRSN 58.8M
- IPO Year
- MDAI N/A
- NRSN 2021
- Fundamental
- Price
- MDAI $2.48
- NRSN $1.91
- Analyst Decision
- MDAI Strong Buy
- NRSN Buy
- Analyst Count
- MDAI 2
- NRSN 2
- Target Price
- MDAI $4.75
- NRSN $14.00
- AVG Volume (30 Days)
- MDAI 503.5K
- NRSN 442.8K
- Earning Date
- MDAI 08-11-2025
- NRSN 07-11-2025
- Dividend Yield
- MDAI N/A
- NRSN N/A
- EPS Growth
- MDAI N/A
- NRSN N/A
- EPS
- MDAI N/A
- NRSN N/A
- Revenue
- MDAI $29,962,000.00
- NRSN N/A
- Revenue This Year
- MDAI N/A
- NRSN N/A
- Revenue Next Year
- MDAI $15.14
- NRSN N/A
- P/E Ratio
- MDAI N/A
- NRSN N/A
- Revenue Growth
- MDAI 55.21
- NRSN N/A
- 52 Week Low
- MDAI $0.82
- NRSN $0.51
- 52 Week High
- MDAI $3.25
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- MDAI 71.31
- NRSN 51.18
- Support Level
- MDAI $2.07
- NRSN $2.04
- Resistance Level
- MDAI $2.22
- NRSN $2.35
- Average True Range (ATR)
- MDAI 0.17
- NRSN 0.25
- MACD
- MDAI 0.01
- NRSN -0.04
- Stochastic Oscillator
- MDAI 75.41
- NRSN 28.74
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.